We agree with the authors about the need for clinical trials to study the effects of intervention with various dietary nutrients in reducing and preventing sarcopenia. References 1. Scott D, Jones G (2013) Impact of nutrition on muscle mass, strength, and performance in older adults. Osteoporos Int. doi:10.1007/s00198-013-2510-7″
“Introduction Osteoporosis is a systemic skeletal disease characterized by micro-architectural CA3 purchase deterioration of bone with resultant low bone mass, bone fragility, and Selleckchem CX 5461 increased fracture risk [1]. Osteoporosis-related
fractures, which most commonly occur at the hip, spine, and wrist, may be followed by full recovery or by chronic pain, disability, and death [1]. Osteoporosis is most prevalent in middle-aged and elderly adults, and currently affects approximately 10 million individuals in the USA [2]. It is estimated that up to 50 % of women and 25 % of GSK872 manufacturer men over the age of 50 years will experience an osteoporotic fracture in their remaining lifetime [2]. The effects of osteoporotic fracture on morbidity and mortality are significant. In a retrospective US Medicare claims database analysis
of over 97,000 patients with vertebral compression fractures, the hazard ratio for mortality vs. control patients was 1.83 (95 % confidence interval [CI], 1.80–1.86) [3]. Similarly, the prospective US Study of Osteoporotic Fractures found that, compared with women without vertebral fracture, women with ≥1 vertebral fracture had a 1.23-fold greater age-adjusted mortality rate (95 % CI, 1.10–1.37) [4]. Mortality increased with the number of vertebral fractures, rising from 19 per 1,000 woman-years in those without fractures to 44 per 1,000 woman-years in those with ≥5 fractures (p for trend <0.001). Osteoporotic fracture-associated morbidity may impact on patients in several ways, including impaired physical functioning, disability, depression, social isolation, pain, loss
of independence, and decreased quality of life [5–7]. Many such consequences can be measured using an appropriate specific patient-reported outcome (PRO) instrument. The Osteoporosis Assessment Questionnaire (OPAQ) versions 1.0, 2.0, and short version are validated, reliable PRO measures used extensively selleck chemicals in clinical trials to assess patient outcomes in individuals with osteoporosis [8–14]. The instruments were developed as disease-targeted questionnaires that would discriminate between postmenopausal women with and without osteoporotic fracture [11], and were also intended to be used as evaluative instruments in clinical trials [11]. The OPAQ v.1.0 contained 84 questions in 18 domains and four dimensions (physical function, emotional status, symptoms, and social interactions), plus 18 questions measuring satisfaction with each of the domains [11]. In 2000, Silverman modified the OPAQ and created v.2.0, a 14-domain, 60-item questionnaire that retained the same four dimensions as v.1.0 [11].